- Home
- REPX vs GERN Comparison
REPX vs GERN Comparison
Compare REPX & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | REPX | GERN |
|---|---|---|
| Founded | 2016 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2003 | 1996 |
Fundamental Metrics
Financial Performance| Metric | REPX | GERN |
|---|---|---|
| Price | $40.48 | $0.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $56.00 | $3.63 |
| AVG Volume (30 Days) | 259.7K | ★ 14.6M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | ★ 78.17 | 51.85 |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $3,038,000.00 | $1,065,000.00 |
| Revenue This Year | $62.29 | $27.99 |
| Revenue Next Year | $6.32 | $44.91 |
| P/E Ratio | $60.61 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $24.09 | $0.84 |
| 52 Week High | $54.57 | $2.01 |
Technical Indicators
Market Signals| Indicator | REPX | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 35.12 | 39.98 |
| Support Level | $32.51 | $0.84 |
| Resistance Level | $41.39 | $1.67 |
| Average True Range (ATR) | 2.46 | 0.09 |
| MACD | -1.61 | -0.00 |
| Stochastic Oscillator | 3.78 | 36.08 |
Price Performance
Historical ComparisonAbout REPX Riley Exploration Permian Inc.
Riley Exploration Permian Inc is engaged in the business of exploration for and production of oil and natural gas. The company operations include: The Permian Basin is an oil and natural gas producing area located in West Texas.
About GERN Geron Corporation
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.